These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36780114)

  • 41. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
    Mercuri E; Baranello G; Boespflug-Tanguy O; De Waele L; Goemans N; Kirschner J; Masson R; Mazzone ES; Pechmann A; Pera MC; Vuillerot C; Bader-Weder S; Gerber M; Gorni K; Hoffart J; Kletzl H; Martin C; McIver T; Scalco RS; Yeung WY; Servais L;
    Eur J Neurol; 2023 Jul; 30(7):1945-1956. PubMed ID: 35837793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis.
    Khuntha S; Prawjaeng J; Ponragdee K; Sanmaneechai O; Srinonprasert V; Leelahavarong P
    Appl Health Econ Health Policy; 2024 Sep; ():. PubMed ID: 39333302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Adult Spinal Muscular Atrophy].
    Walter MC; Hiebeler M
    Fortschr Neurol Psychiatr; 2022 Sep; 90(9):421-430. PubMed ID: 36103897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy.
    Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Vázquez-Costa JF
    Muscle Nerve; 2023 May; 67(5):407-411. PubMed ID: 36815750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances and limitations for the treatment of spinal muscular atrophy.
    Day JW; Howell K; Place A; Long K; Rossello J; Kertesz N; Nomikos G
    BMC Pediatr; 2022 Nov; 22(1):632. PubMed ID: 36329412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy.
    Mendell JR; Al-Zaidy SA; Lehman KJ; McColly M; Lowes LP; Alfano LN; Reash NF; Iammarino MA; Church KR; Kleyn A; Meriggioli MN; Shell R
    JAMA Neurol; 2021 Jul; 78(7):834-841. PubMed ID: 33999158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy.
    Li Y; Zeng H; Wei Y; Ma X; He Z
    Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction.
    Bjelica B; Wohnrade C; Cespedes I; Osmanovic A; Schreiber-Katz O; Petri S
    BMC Neurol; 2024 Feb; 24(1):67. PubMed ID: 38368338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spinal Muscular Atrophy Scoliosis in the Era of Background Therapies-A Review of the Literature.
    Ruythooren F; Moens P
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38929996
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides.
    Torroba B; Macabuag N; Haisma EM; O'Neill A; Herva ME; Redis RS; Templin MV; Black LE; Fischer DF
    Expert Opin Drug Discov; 2023 Feb; 18(2):181-192. PubMed ID: 36408582
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance.
    Keinath MC; Prior DE; Prior TW
    Appl Clin Genet; 2021; 14():11-25. PubMed ID: 33531827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children.
    Cleary Y; Kletzl H; Grimsey P; Heinig K; Ogungbenro K; Silber Baumann HE; Frey N; Aarons L; Galetin A; Gertz M
    Clin Pharmacokinet; 2023 Jun; 62(6):891-904. PubMed ID: 37148485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Spinal muscular atrophy].
    Martin P; Horber V; Park J; Kronlage C; Grimm A
    Nervenarzt; 2022 Feb; 93(2):191-200. PubMed ID: 35037967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on page 264.
    Poletti A; Fischbeck KH
    J Neurochem; 2020 Apr; 153(2):146-149. PubMed ID: 32056234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
    Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
    Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in the Incidence of Infantile Spinal Muscular Atrophy in Shikoku, Japan between 2011 and 2020.
    Okamoto K; Nishio H; Motoki T; Jogamoto T; Aibara K; Kondo Y; Kawamura K; Konishi Y; Tokorodani C; Nishiuchi R; Eguchi M
    Int J Neonatal Screen; 2022 Sep; 8(4):. PubMed ID: 36278622
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I.
    Mirea A; Shelby ES; Axente M; Badina M; Padure L; Leanca M; Dima V; Sporea C
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884240
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy.
    Singh RN; Ottesen EW; Singh NN
    Neurosci Insights; 2020; 15():2633105520973985. PubMed ID: 33283185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.